Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended September 30, 2011. The registrant is an Australian entity admitted on the basis of commitments, reporting under Appendix 4C rules. The filing was signed on October 27, 2011.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Receipts from Customers | 0 |
| Net Operating Cash Flows | (1,784) |
| Net Investing Cash Flows | 0 |
| Net Financing Cash Flows | 1,241 |
| Net Decrease in Cash | (543) |
| Cash at End of Quarter | 8,466 |
| Proceeds from Share Issues | 1,253 |
| Capital Raising Costs | (12) |
| Staff Costs Paid | (657) |
| R&D Costs Paid | (640) |
| Grants Received | 100 |
Debt and Liquidity: The company reported no borrowings, no repayments of borrowings, and no available loan facilities or credit standby arrangements. Liquidity is maintained through cash on hand and at bank totaling $8.466 million.
Material Changes
The filing does not provide comparative financial data for the prior year or prior quarter to calculate percentage changes in revenue or profit. However, the cash balance decreased by $543,000 during the quarter, primarily due to operating outflows exceeding financing inflows. There were no acquisitions or disposals of business entities reported.
Outlook, Risks, and Commentary
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard compliance statements. The company continues to operate with no revenue, relying on share issuances and grants to fund operations. Related party transactions totaled $375,000, described as salaries, directors' fees, and consulting fees at normal commercial rates.
Investor Verification Checklist
- Verify the company name discrepancy between the metadata (Altery Therapeutics Ltd) and the filing (Prana Biotechnology Limited).
- Confirm the sustainability of operations given zero revenue and a net operating cash burn of $1.784 million per quarter.
- Assess the adequacy of the $8.466 million cash balance against the current burn rate and future capital requirements.
- Review the terms of the $1.253 million share issuance to understand dilution impact.
- Investigate the nature of the $100,000 in grants received and any conditions attached.